Evaluation and Management of Hair Loss with Elevated DHEA
In patients with elevated DHEA and hair loss, you must first measure total testosterone (preferably by LC/MS) and DHEA-sulfate (DHEAS) to determine if true hyperandrogenism exists, then initiate treatment with topical minoxidil 5%, adding antiandrogens or 5α-reductase inhibitors only if severe hair loss or confirmed hyperandrogenism is present. 1
Critical Diagnostic Framework
Initial Androgen Assessment (Mandatory)
The 2019 Androgen Excess and PCOS Society guidelines are explicit: assessment of androgen excess is mandatory in all patients with female pattern hair loss (FPHL) 1. However, the relationship between DHEA elevation and hair loss is nuanced:
- Measure total testosterone using high-quality assay (LC/MS preferred) and free testosterone (via equilibrium dialysis or calculated using SHBG) 1
- Measure DHEAS - this is critical because DHEA alone may not reflect true hyperandrogenism 2
- If testosterone is twice the upper limit of normal, DHEAS becomes essential for localization: DHEAS >600 μg/dL suggests adrenal source 2
Important caveat: Most women with FPHL have normal circulating androgen levels despite hair loss 1. The presence of hair loss alone, even with elevated DHEA, should not automatically be considered hyperandrogenism unless androgen levels are truly elevated 1.
Additional Laboratory Evaluation (Recommended but Optional)
While not mandatory, these tests help identify treatable contributing factors 1:
- Iron studies (ferritin) - though evidence for treatment benefit is weak 1
- Vitamin D (25-hydroxyvitamin D) - low in 62% of FPHL patients 1
- Zinc levels - low in 15% of FPHL patients 1
- Thyroid function (TSH, free T4) - hypothyroidism may contribute 1, 3
- Prolactin - elevated levels may have androgen-stimulating effects 1
Treatment Algorithm
First-Line Treatment: Topical Minoxidil
Start with topical minoxidil 5% (solution or foam) regardless of androgen status 1:
- 5% formulation is superior to 2% for efficacy 1
- 5% foam once daily equals 2% solution twice daily in effectiveness 1
- Warn patients about initial shedding at 2-8 weeks (telogen hairs preparing for anagen growth) 1
- Minimum 12-month trial required for optimal results 1
- Side effects: scalp pruritus/flaking (more common with solution due to propylene glycol), facial hypertrichosis (more common with 5%) 1
Second-Line: Add Antiandrogens or 5α-Reductase Inhibitors
Add systemic therapy only when 1:
- Severe hair loss is present, OR
- Confirmed hyperandrogenism exists (elevated testosterone/free testosterone)
This is where confirmed androgen elevation matters clinically. The guidelines specifically state combination therapy enhances results in these specific scenarios 1.
Key Clinical Pitfalls
The DHEA Elevation Paradox
Older research from 1987 showed elevated DHEAS in young men with male pattern baldness 4, and some studies suggest adrenal hyperactivity may initiate alopecia in genetically susceptible individuals 4. However, the 2019 expert consensus emphasizes that isolated FPHL should NOT be considered hyperandrogenism when androgen levels are normal 1.
What this means clinically: An elevated DHEA alone, without elevated testosterone or free testosterone, does not warrant antiandrogen therapy. The hair loss may be occurring through non-androgenic mechanisms or reflect altered estrogen-to-androgen ratios rather than absolute androgen excess 5.
Normal Androgens Don't Exclude Hormonal Influence
When testosterone is normal but clinical hyperandrogenism signs exist (hirsutism, acne), consider 2:
- SHBG levels - commonly reduced with obesity, metabolic syndrome, or family history of diabetes
- This lowers free (bioavailable) testosterone even when total testosterone appears normal
- The estradiol-to-free testosterone ratio may be more relevant than absolute levels 5
Stress and Cortisol Connection
Multiple studies show elevated cortisol in both male and female patients with androgenic hair loss 6, pointing to adrenal involvement. This explains why hair loss often worsens during stress periods 6. While not directly treatable, this reinforces the multifactorial nature beyond simple androgen elevation.
Clinical Decision Point
If DHEA is elevated but testosterone/free testosterone are normal: Treat as standard FPHL with minoxidil 5% monotherapy. Do not add antiandrogens 1.
If both DHEA and testosterone are elevated: This represents true hyperandrogenism warranting combination therapy with minoxidil plus antiandrogens/5α-reductase inhibitors 1.
The distinction is critical because antiandrogen therapy carries additional risks and should be reserved for patients who will actually benefit based on confirmed androgen excess, not isolated DHEA elevation.